PCSK9 Inhibitors: Economics and Policy

Journal of the American College of Cardiology

Volumn 70, Issue 21, 2017, Pages 2677-2687

  Hlatky, Mark A ^a   Kazi, Dhruv S ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

cost effectiveness; prevention; society

Indexed keywords

ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9 INHIBITOR; UNCLASSIFIED DRUG; ALIROCUMAB; EVOLOCUMAB; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9; TRASTUZUMAB;

CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SOCIETY; UNITED STATES; ANTAGONISTS AND INHIBITORS; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; ECONOMICS, MEDICAL; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT COMPLIANCE; PROPROTEIN CONVERTASE 9; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRASTUZUMAB; TREATMENT OUTCOME; UNITED STATES;

EID: 85033700437     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.10.001     Document Type: Review

References (44)

1. Abided, M., Varret, M., Rabès, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet 34 (2003), 154–156.
2. Kotowski, I.K., Pertsemlidis, A., Luke, A., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Human Genet 78 (2006), 410–422.
3. Cohen, J.C., Boerwinkle, E., Mosley, T.H., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006), 1264–1272.
4. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
5. Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
6. Navarese, E.P., Kolodziejczak, M., Schulze, V., et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. Ann Intern Med 163 (2015), 40–51.
7. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
8. Ridker, P.M., Revkin, J., Amarenco, P., et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376 (2017), 1527–1539.
9. Schwartz, G.G., Bessac, L., Berdan, L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168 (2014), 682–689.e681.
10. Sanders, G.D., Neumann, P.J., Basu, A., et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316 (2016), 1093–1103.
11. Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost-value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
12. McConnachie, A., Walker, A., Robertson, M., et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 35 (2014), 290–298.
13. Mihaylova, B., Schlackow, I., Herrington, W., et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 67 (2015), 576–584.
14. Goldman, L., Weinstein, M.C., Goldman, P.A., Williams, L.W., Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265 (1991), 1145–1152.
15. Prosser, L.A., Stinnett, A.A., Goldman, P.A., et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 132 (2000), 769–779.
16. Kazi, D.S., Moran, A.E., Coxson, P.G., et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316 (2016), 743–753.
17. Pandya, A., Sy, S., Cho, S., Weinstein, M.C., Gaziano, T.A., Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 314 (2015), 142–150.
18. Kazi, D.S., Penko, J., Coxson, P.G., et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 318 (2017), 748–750.
19. Gandra, S.R., Villa, G., Fonarow, G.C., et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol 39 (2016), 313–320.
20. Toth, P.P., Danese, M., Villa, G., et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ 20 (2017), 555–564.
21. Fonarow, G.C., Keech, A.C., Pedersen, T.R., et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2 (2017), 1069–1078.
22. Arrieta, A., Page, T.F., Veledar, E., Nasir, K., Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One, 12, 2017, e0169761.
23. Arrieta, A., Hong, J.C., Khera, R., Virani, S.S., Krumholz, H.M., Nasir, K., Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol, 2017 Oct 18 [E-pub ahead of print].
24. Jena, A.B., Blumenthal, D.M., Stevens, W., Chou, J.W., Ton, T.G.N., Goldman, D.P., Value of improved lipid control in patients at high risk for adverse cardiovacular events. Am J Manag Care 22 (2016), e199–e207.
25. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
26. Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380 (2012), 581–590.
27. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
28. Linkoff, A.M., Nicholls, S.J., Risemeyer, J.S., et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 376 (2017), 1933–1942.
29. Ridker, P.M., Tardif, J.C., Amarenco, P., et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med 376 (2017), 1517–1526.
30. Sailstad, J.M., Amaravadi, L., Clements-Egan, A., et al. A white paper—consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J 16 (2014), 488–498.
31. Downing, N.S., Shah, N.D., Aminawung, J.A., et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 317 (2017), 1854–1863.
32. Dusetzina, S.B., Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000–2014. JAMA Oncol 2 (2016), 960–961.
33. Lotvin, A.M., Shrank, W.H., Singh, S.C., Falit, B.P., Brennan, T.A., Specialty medications: Traditional and novel tools can address rising spending on these costly drugs. Health Aff 33 (2014), 1736–1744.
34. Virani, S.S., Akeroyd, J.M., Nambi, V., et al. Estimation of eligibility for PCSK9 inhibitors and associated costs based on the FOURIER trials: insights from the Department of Veterans Affairs. Circulation 135 (2017), 2572–2574.
35. Schulman, K.A., Balu, S., Reed, S.D., Specialty pharmaceuticals for hyperlipidemia—impact on insurance premiums. N Engl J Med 373 (2015), 1591–1593.
36. Hatch OG, Wyden R. The price of sovaldi and its impact on the U.S. Health Care System. Available at: http://www.finance.senate.gov/download/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report. Accessed July 1, 2017.
37. National Institute for Health and Care Excellence (NICE). Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance. June 22, 2016. Available at: http://www.nice.org.uk/guidance/ta393. Accessed April 26, 2017.
38. National Institute for Health and Care Excellence (NICE). Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance. June 22, 2016. Available at: http://www.nice.org.uk/guidance/ta394 April 26, 2017.
39. Sanofi. Appeals court grants stay of permanent injunction for Praluent (alirocumab) during appeals process. February 8, 2017. Available at: http://www.news.sanofi.us/Appeals-Court-Grants-Stay-of-Permanent-Injunction-for-Praluent-R-alirocumab-During-Appeals-Process. Accessed June 14, 2017.
40. Knowles, J.W., Howard, W.B., Karayan, L., et al. Access to non-statin therapies in patients at high risk of atherosclerotic cardiovascular disease. Circulation 135 (2017), 2204–2206.
41. Navar AM, Taylor BT, Flevitz E. Early challenges for PCSK9 inhibitor prescriptions and patients: rejections and rates unfilled. Abstract 415-08. Paper presented at: 66th Scientific Session of the American College of Cardiology; March 17–19, 2017; Washington, DC.
42. Baum SJ, Chen CC, Rane PB. Characteristics of patients approved and denied access in PCSK9i therapy by payers. Abstract 1258-435. Paper presented at: 66th Scientific Session of the American College of Cardiology; March 17–19, 2017; Washington, DC.
43. Kazi, D.S., Lu, C.Y., Lin, G.A., et al. Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans. JAMA Cardiol 2 (2017), 1164–1166.
44. Newman, C.B., Tobert, J.A., Statin intolerance. Reconciling clinical trials and clinical experience. JAMA 313 (2015), 1011–1012.